<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05016622</url>
  </required_header>
  <id_info>
    <org_study_id>2021-13204</org_study_id>
    <nct_id>NCT05016622</nct_id>
  </id_info>
  <brief_title>Booster Dose Trial</brief_title>
  <official_title>Safety and Efficacy of Booster Doses of BNT162b2 Vaccine in Immunocompromised Patients With a Cancer Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to assess the safety and effectiveness of a COVID vaccine booster&#xD;
      in patients with cancer who have not developed an antibody after the U.S. Food and Drug&#xD;
      Administration (FDA) Emergency Use Authorized COVID vaccination series&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of seroconversion for SARS-CoV-2 spike antibody</measure>
    <time_frame>4 weeks after booster dose</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Booster dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BNT162b2 vaccine</intervention_name>
    <description>administer an additional dose of the BNT162b2 mRNA vaccine to patients with cancer who have a negative SARS-CoV-2 Spike IgG at least 14 days after 2 doses of the mRNA vaccines (BNT162b2/mRNA-1273) or 28 days after the adenoviral based Ad26CoV2.S vaccine.</description>
    <arm_group_label>Booster dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Above the age of 18&#xD;
&#xD;
          -  Known diagnosis of any malignancy- either active or completed therapy&#xD;
&#xD;
          -  Underwent an in-person encounter at a study facility during the study period&#xD;
&#xD;
          -  Have a negative SARS-CoV-2 spike IgG at least 14 days after the second dose of the&#xD;
             mRNA-based vaccines (Moderna or Pfizer/BioNTech) or 28 days after a single dose of the&#xD;
             adenovirus-based Johnson &amp; Johnson vaccine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had a serious adverse reaction to any prior COVID-19 vaccines&#xD;
             resulting in emergency room visit or hospitalization, had events related to&#xD;
             myocarditis, thrombosis and thrombocytopenia syndrome or anaphylaxis to any prior dose&#xD;
             of the COVID-19 vaccines.&#xD;
&#xD;
          -  Patients who have had a documented COVID-19 infection in the 90 days prior to starting&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Markenya Mirander</last_name>
    <phone>718-379-6863</phone>
    <email>mmirande@montefiore.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Booster</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

